You are here: Industry Insights > COVID-19 vaccine

News List

MilliporeSigma, Baylor College of Medicine to Advance COVID-19 Vaccine Manufacturing Platform americanpharmaceuticalreview
May 29, 2020
MilliporeSigma and Baylor College of Medicine have announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase 1 clinical trials.
mRNA-based vaccine technology innovate approach to treating COVID-19 expresspharma
May 29, 2020
Over 150 COVID-19 vaccines are currently under development by biopharma companies and research organisations around the world.
Novartis inks deal to make Mass General Brigham’s COVID-19 vaccine candidate expresspharma
May 29, 2020
AveXis, which makes Novartis’s $2.1 million-per-patient gene therapy Zolgensma for the hereditary disease spinal muscular atrophy, is contributing technology, expertise and its manufacturing supply chain at no cost.
EMA commissions research in preparation for monitoring COVID-19 vaccines europeanpharmaceuticalreview
May 28, 2020
The research will identify sources of data to monitor coverage and effectiveness, and support pharmacovigilance of COVID-19 vaccines once they are approved.
Vaxine and Medytox partner on Covid-19 vaccine development pharmaceutical-technology
May 27, 2020
Australian biotechnology company Vaxine has collaborated with South Korean biopharma firm Medytox for the development and commercialisation of its Covid-19 vaccine candidate, COVAX-19.
Canada’s USask reports positive preclinical data for Covid-19 vaccine pharmaceutical-technology
May 27, 2020
The University of Saskatchewan (USask) in Canada has reported positive data from preclinical studies of the Covid-19 vaccine candidate developed by its Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac).
COVID-19 vaccine induces immune response in Phase I trial europeanpharmaceuticalreview
May 27, 2020
The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.
Merck to Acquire Themis contractpharma
May 27, 2020
Will apply its vaccine development capabilities to SARS-CoV-2 vaccine program originated by Themis and Institut Pasteur.
First COVID-19 vaccine human trial finds it is safe, induces immune response expresspharma
May 27, 2020
According to the study of 108 adults, the vaccine produced neutralising antibodies, and a response mediated by the immune system's T-cells against the novel coronavirus, SARS-CoV-2.
Project leader: Oxford’s COVID-19 vaccine trial has 50 per cent chance of success expresspharma
May 27, 2020
The experimental vaccine, known as ChAdOx1 nCoV-19, is one of the front-runners in the global race to provide protection against the new coronavirus causing the COVID-19 pandemic.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 116 117 Next page